SCHEMBL23938110

SCHEMBL23938110

Cc1cnc2c(N)csc2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
UHRF1 Q96T88 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CDC7 O00311 1/20 0.31
PLK4 O00444 1/20 0.31
IKBKB O14920 1/20 0.31
AURKA O14965 1/20 0.31
CHUK O15111 1/20 0.31
ROCK2 O75116 1/20 0.31
FYN P06241 1/20 0.31
PIM1 P11309 1/20 0.31
PRKACA P17612 1/20 0.31
RPS6KB1 P23443 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24284148 0.80 PDPK1 (0.34) NOS1SMN1; SMN2KDM4ENPC1IRAK4
SCHEMBL20731139 0.69 IKBKB (0.37) NOS1SMN1; SMN2KDM4ENPC1USP2
SCHEMBL28739202 0.69 KDM4E (0.35) KDM4ENPC1USP2ALDH1A1MAPT
SCHEMBL20731810 0.69 LIMK1 (0.38) NOS1SMN1; SMN2KDM4ENPC1USP2
SCHEMBL30272027 0.69 KDM4E (0.35) KDM4ENPC1USP2ALDH1A1MAPT
SCHEMBL22224010 0.68 PDPK1 (0.34) NOS1SMN1; SMN2NPC1
SCHEMBL11488960 0.67 ALDH1A1 (0.45) NOS1SMN1; SMN2KDM4ENPC1USP2
SCHEMBL23938027 0.66 MAP4K4 (0.31)
SCHEMBL5802822 0.65 KDM4E (0.45) NOS1SMN1; SMN2KDM4EUSP2ALDH1A1
SCHEMBL30061268 0.65 KDM4E (0.45) NOS1SMN1; SMN2KDM4EUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US claimed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 NOS1 3870/4885SMN1; SMN2 2918/4885UHRF1 119/4885
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 NOS1 3870/4885SMN1; SMN2 2918/4885UHRF1 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.